AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2700 companies scored · 2026-10-16 run in progress: 1425 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-15 run
Companies scored 2700 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.31% Alpha · 90D
Long–short spread +5.08% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 379 ▼ 472 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

301 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
251 LFCRLIFECORE BIOMEDICAL, INC. \DE\ Life Sciences 0.30 $244M Neutral -0.37% -0.76% ·
252 AMRNAMARIN CORP PLC\UK Life Sciences 0.05 $243M Neutral +0.07% +0.17% ·
253 SABSSAB Biotherapeutics, Inc. Life Sciences 0.15 $236M Neutral -0.09% -0.14% ·
254 IMRXImmuneering Corp Life Sciences 0.26 $235M Unlock rating and forecasts
255 FATEFATE THERAPEUTICS INC Life Sciences 0.11 $231M Unlock rating and forecasts
256 LXEOLexeo Therapeutics, Inc. Life Sciences 0.06 $226M Unlock rating and forecasts
257 GLSIGreenwich LifeSciences, Inc. Life Sciences 0.11 $225M Unlock rating and forecasts
258 SIGASIGA TECHNOLOGIES INC Life Sciences 0.47 $223M Neutral +0.23% +0.16% ·
259 NATRNATURES SUNSHINE PRODUCTS INC Life Sciences 0.56 $222M Unlock rating and forecasts
260 KROSKeros Therapeutics, Inc. Life Sciences 0.15 $220M Neutral -0.04% -0.04% ·
261 PLXProtalix BioTherapeutics, Inc. Life Sciences 0.02 $218M Unlock rating and forecasts
262 ALECAlector, Inc. Life Sciences 0.24 $213M Unlock rating and forecasts
263 NAGENiagen Bioscience, Inc. Life Sciences 0.59 $204M Neutral -0.38% -0.81% ·
264 RNACCartesian Therapeutics, Inc. Life Sciences 0.36 $199M Unlock rating and forecasts
265 IVVDInvivyd, Inc. Life Sciences 0.05 $197M Unlock rating and forecasts
266 AKBAAkebia Therapeutics, Inc. Life Sciences 0.10 $193M Unlock rating and forecasts
267 ADCTADC Therapeutics SA Life Sciences 0.30 $190M Unlock rating and forecasts
268 CGENCOMPUGEN LTD Life Sciences 0.42 $189M Neutral -0.10% -0.22% ·
269 ACOGAlpha Cognition Inc. Life Sciences 0.62 $188M Unlock rating and forecasts
270 UPBUpstream Bio, Inc. Life Sciences 0.64 $187M Unlock rating and forecasts
271 SIONSionna Therapeutics, Inc. Life Sciences 0.04 $185M Unlock rating and forecasts
272 TRDAEntrada Therapeutics, Inc. Life Sciences 0.20 $177M Unlock rating and forecasts
273 PEPGPepGen Inc. Life Sciences 0.26 $175M Unlock rating and forecasts
274 STROSUTRO BIOPHARMA, INC. Life Sciences 0.59 $174M Unlock rating and forecasts
275 ORMPORAMED PHARMACEUTICALS INC. Life Sciences 0.07 $174M Unlock rating and forecasts
276 ZNTLZentalis Pharmaceuticals, Inc. Life Sciences 0.31 $166M Unlock rating and forecasts
277 CHRSCoherus Oncology, Inc. Life Sciences 0.21 $165M Unlock rating and forecasts
278 CMPXCompass Therapeutics, Inc. Life Sciences 0.16 $161M Unlock rating and forecasts
279 MDWDMediWound Ltd. Life Sciences 0.25 $153M Neutral -0.11% -0.80% ▲ 1
280 NBPNovaBridge Biosciences Life Sciences 0.18 $149M Neutral -0.29% -0.56% ·
281 MOLNMOLECULAR PARTNERS AG Life Sciences 0.04 $147M Neutral -0.10% +0.14% ·
282 TARAProtara Therapeutics, Inc. Life Sciences 0.16 $147M Unlock rating and forecasts
283 ORGOOrganogenesis Holdings Inc. Life Sciences 0.33 $143M Unlock rating and forecasts
284 DERMJourney Medical Corp Life Sciences 0.15 $139M Unlock rating and forecasts
285 NKTXNkarta, Inc. Life Sciences 0.03 $138M Unlock rating and forecasts
286 KRROKorro Bio, Inc. Life Sciences 0.13 $137M Unlock rating and forecasts
287 ANTXAN2 Therapeutics, Inc. Life Sciences 0.36 $136M Unlock rating and forecasts
288 HUMAHumacyte, Inc. Life Sciences 0.12 $122M Unlock rating and forecasts
289 OTLKOutlook Therapeutics, Inc. Life Sciences 0.48 $122M Unlock rating and forecasts
290 NERVMinerva Neurosciences, Inc. Life Sciences 0.14 $116M Unlock rating and forecasts
291 ENGNenGene Therapeutics Inc. Life Sciences 0.32 $115M Neutral +0.01% +0.06% ▼ 2
292 ARMPArmata Pharmaceuticals, Inc. Life Sciences 0.12 $112M Unlock rating and forecasts
293 CLLSCellectis S.A. Life Sciences 0.13 $112M Neutral +1.29% -0.04% ·
294 FHTXFoghorn Therapeutics Inc. Life Sciences 0.12 $112M Unlock rating and forecasts
295 LENZLENZ Therapeutics, Inc. Life Sciences 0.55 $112M Unlock rating and forecasts
296 SPRBSPRUCE BIOSCIENCES, INC. Life Sciences 0.01 $112M Neutral +0.27% -0.67% ▲ 1
297 MISTMilestone Pharmaceuticals Inc. Life Sciences 0.07 $112M Unlock rating and forecasts
298 INOINOVIO PHARMACEUTICALS, INC. Life Sciences 0.25 $108M Unlock rating and forecasts
299 GNLXGENELUX Corp Life Sciences 0.33 $105M Unlock rating and forecasts
300 UNCYUnicycive Therapeutics, Inc. Life Sciences 0.12 $103M Unlock rating and forecasts
251–300 of 301 Previous Next
Since the previous run

Rating changes

▲ 379▼ 472
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.